Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8495)
All Articles published online
|
Publishing Process of This Article
|
Nov 7, 2014 (publication date) through Apr 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sudo K, Nakamura K, Yamaguchi T. S-1 in the treatment of pancreatic cancer. World J Gastroenterol 2014; 20(41): 15110-15118 [PMID: 25386059 DOI: 10.3748/wjg.v20.i41.15110] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v20/i41/15110.htm |
| Number | Citing Articles |
| 1 |
Ryoichi Miyamoto, Yukio Oshiro, Naoki Sano, Satoshi Inagawa, Nobuhiro Ohkohchi. Remnant pancreatic volume as an indicator of poor prognosis in pancreatic cancer patients after resection. Pancreatology 2019; 19(5): 716 doi: 10.1016/j.pan.2019.05.464
|
| 2 |
伟 王. Research Prospect of Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer. Advances in Clinical Medicine 2022; 12(12): 11459 doi: 10.12677/ACM.2022.12121651
|
| 3 |
Satoshi Okubo, Motohiro Kojima, Yoko Matsuda, Masayoshi Hioki, Yasuhiro Shimizu, Hirochika Toyama, Soichiro Morinaga, Naoto Gotohda, Katsuhiko Uesaka, Genichiro Ishii, Mari Mino-Kenudson, Shinichiro Takahashi. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-53801-2
|
| 4 |
Makoto Nishikawa, Suefumi Aosasa, Tomoyuki Moriya, Takuji Noro, Kazuo Hase, Junji Yamamoto. The impact of postoperative adjuvant chemotherapy on the development of nonalcoholic fatty liver disease after pancreatoduodenectomy. Journal of Surgical Research 2016; 205(1): 127 doi: 10.1016/j.jss.2015.12.013
|
| 5 |
Kosei Takagi, Takahito Yagi, Takehiro Tanaka, Yuzo Umeda, Ryuichi Yoshida, Daisuke Nobuoka, Takashi Kuise, Toshiyoshi Fujiwara. Primary pancreatic-type acinar cell carcinoma of the jejunum with tumor thrombus extending into the mesenteric venous system: a case report and literature review. BMC Surgery 2017; 17(1) doi: 10.1186/s12893-017-0273-3
|
| 6 |
Yunlong Chen, Jiangning Gu, Menghong Yin, Chenqi Wang, Dan Chen, Lili Yang, Xiang Chen, Zhikun Lin, Jian Du, Shimeng Cui, Chi Ma, Haifeng Luo. Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patients. Medicine 2021; 100(25): e26342 doi: 10.1097/MD.0000000000026342
|
| 7 |
S. Hoshimoto, S. Hishinuma, H. Shirakawa, M. Tomikawa, I. Ozawa, S. Wakamatsu, S. Hoshi, N. Hoshi, K. Hirabayashi, Y. Ogata. Reassessment of the clinical significance of portal–superior mesenteric vein invasion in borderline resectable pancreatic cancer. European Journal of Surgical Oncology (EJSO) 2017; 43(6): 1068 doi: 10.1016/j.ejso.2017.03.020
|
| 8 |
Aleksandra Adamska, Alice Domenichini, Marco Falasca. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. International Journal of Molecular Sciences 2017; 18(7): 1338 doi: 10.3390/ijms18071338
|
| 9 |
Shigeo Koido, Masato Okamoto, Shigetaka Shimodaira, Haruo Sugiyama. Wilms’ tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer. Immunotherapy 2016; 8(11): 1309 doi: 10.2217/imt-2016-0031
|
| 10 |
Dietrich A. Ruess, Kivanc Görgülü, Sonja M. Wörmann, Hana Algül. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs & Aging 2017; 34(5): 331 doi: 10.1007/s40266-017-0453-y
|
| 11 |
Ryoichi Miyamoto, Tatsuya Oda, Shinji Hashimoto, Tomohiro Kurokawa, Keisuke Kohno, Yoshimasa Akashi, Yusuke Ohara, Keiichi Yamada, Tsuyoshi Enomoto, Nobuhiro Ohkohchi. Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer. Pancreas 2017; 46(1): 35 doi: 10.1097/MPA.0000000000000697
|
| 12 |
Akihito Machinaga, Yuichi Hori, Kazuya Shimizu, Kyohei Okahara, Emmy Yanagita, Makoto Miyoshi, Tomoo Itoh, Ken Sasai. Xenografts Derived From Patients' Ascites Recapitulate the Gemcitabine Resistance Observed in Pancreatic Cancer Patients. Pancreas 2019; 48(10): 1294 doi: 10.1097/MPA.0000000000001438
|
| 13 |
Matthew J. Reilley, Gauri R. Varadhachary. Multimodality Management of Borderline Resectable Pancreatic Cancer. 2016; : 91 doi: 10.1007/978-3-319-22780-1_6
|
| 14 |
Tae Kim, Soyoung Shin, Jeong Shin, Jürgen Bulitta, Kwon-Yeon Weon, Sun Yoo, Gi-Young Park, Seok Jeong, Dong Kwon, Byung Min, Mi Woo, Beom Shin. Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling. Molecules 2017; 22(9): 1488 doi: 10.3390/molecules22091488
|
| 15 |
Xiaohui Zhang, Lisa Detering, Deborah Sultan, Hannah Luehmann, Lin Li, Gyu Seong Heo, Xiuli Zhang, Lanlan Lou, Patrick M. Grierson, Suellen Greco, Marianna Ruzinova, Richard Laforest, Farrokh Dehdashti, Kian-Huat Lim, Yongjian Liu. CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. ACS Nano 2021; 15(1): 1186 doi: 10.1021/acsnano.0c08185
|
| 16 |
Hong Zhu, Cheng Yi, Yaqin Zhao, Hongfeng Gou. Gemcitabine plus S-1 for metastatic pancreatic cancer. Medicine 2018; 97(41): e12836 doi: 10.1097/MD.0000000000012836
|
| 17 |
Atsuhiko Ueda, Nozomu Sakai, Hideyuki Yoshitomi, Katsunori Furukawa, Tsukasa Takayashiki, Satoshi Kuboki, Shigetsugu Takano, Daisuke Suzuki, Shingo Kagawa, Takashi Mishima, Eri Nakadai, Masaru Miyazaki, Masayuki Ohtsuka. Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer?. World Journal of Surgical Oncology 2019; 17(1) doi: 10.1186/s12957-019-1667-8
|
| 18 |
Tsuyoshi Kono, Masuo Kondoh, Daisuke Kyuno, Tatsuya Ito, Yasutoshi Kimura, Masafumi Imamura, Takayuki Kohno, Takumi Konno, Tomohisa Furuhata, Norimasa Sawada, Koichi Hirata, Takashi Kojima. Claudin‐4 binder C‐CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway. Pharmacology Research & Perspectives 2015; 3(6) doi: 10.1002/prp2.196
|
| 19 |
Scott D. Haller, Michael L. Monaco, Karim Essani. The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer. Viruses 2020; 12(11): 1318 doi: 10.3390/v12111318
|
| 20 |
Terumi Kamisawa, Laura D Wood, Takao Itoi, Kyoichi Takaori. Pancreatic cancer. The Lancet 2016; 388(10039): 73 doi: 10.1016/S0140-6736(16)00141-0
|
| 21 |
Mamoon Ur Rashid, Ishtiaq Hussain, Sundas Jehanzeb, Waqas Ullah, Saeed Ali, Akriti Gupta Jain, Ranjeet Kumar, Neelam Khetpal, Sarfraz Ahmad. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. 2019; : 57 doi: 10.1016/B978-0-12-817661-0.00005-6
|
| 22 |
Juan Wei, XiaoFang Dong, FangMing Du, Sheng Tang, HangPing Wei. Successful gamma knife radiosurgery combined with S-1 in an elderly man with local recurrent pancreatic cancer. Medicine 2017; 96(51): e9338 doi: 10.1097/MD.0000000000009338
|
| 23 |
Weiting Liao, Jiaxing Huang, Guiqi Zhu, Jing Zhou, Feng Wen, Pengfei Zhang, Kexun Zhou, Qiuji Wu, Xinyuan Wang, Hongfeng Gou, Qiu Li. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial. Expert Review of Pharmacoeconomics & Outcomes Research 2020; 20(1): 133 doi: 10.1080/14737167.2020.1677155
|
| 24 |
Kimihiko Funahashi, Tetsuo Nemoto, Junichi Koike, Akiharu Kurihara, Hiroyuki Shiokawa, Mistunori Ushigome, Tomoaki Kaneko, Kenichiro Arai, Yasuo Nagashima, Takamaru Koda, Takayuki Suzuki, Satoru Kagami, Yu Suitsu, Hironori Kaneko, Toshikazu Shibuya. Chemoradiation therapy with S-1 for primary squamous cell carcinoma of the rectum: report of three cases. Surgical Case Reports 2015; 1(1) doi: 10.1186/s40792-015-0025-5
|
| 25 |
Rosella Spadi, Federica Brusa, Agostino Ponzetti, Isabella Chiappino, Nadia Birocco, Libero Ciuffreda, Maria Antonietta Satolli. Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World Journal of Clinical Oncology 2016; 7(1): 27-43 doi: 10.5306/wjco.v7.i1.27
|
| 26 |
Angel Cid-Arregui, Victoria Juarez. Perspectives in the treatment of pancreatic adenocarcinoma. World Journal of Gastroenterology 2015; 21(31): 9297-9316 doi: 10.3748/wjg.v21.i31.9297
|
| 27 |
Atsushi Oba, Daisuke Ban, Susumu Kirimura, Keiichi Akahoshi, Yusuke Mitsunori, Satoshi Matsumura, Takanori Ochiai, Atsushi Kudo, Shinji Tanaka, Tanabe Minoru. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma. Journal of Hepato-Biliary-Pancreatic Sciences 2016; 23(8): 480 doi: 10.1002/jhbp.366
|
| 28 |
Bo Li, Shuo Shen, Siting You, Guoxiao Zhang, Suizhi Gao, Xiaohan Shi, Huan Wang, Xiaoyi Yin, Xiongfei Xu, Shiwei Guo, Gang Jin. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma. BMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-08380-9
|
| 29 |
Yumi Harano, Akira Babazono, Takako Fujita, Peng Jiang. Efficacy of S-1 monotherapy for older patients with unresectable pancreatic cancer: A retrospective cohort study. Journal of Geriatric Oncology 2019; 10(3): 420 doi: 10.1016/j.jgo.2018.09.004
|
| 30 |
Yusuke Yamaoka, Tomohiro Yamaguchi, Yusuke Kinugasa, Akio Shiomi, Hiroyasu Kagawa, Yushi Yamakawa, Masakatsu Numata, Shinya Sugimoto, Kenichiro Imai, Kinichi Hotta, Keiko Sasaki. Adenocarcinoma arising from jejunal ectopic pancreas mimicking peritoneal metastasis from colon cancer: a case report and literature review. Surgical Case Reports 2015; 1(1) doi: 10.1186/s40792-015-0118-1
|
| 31 |
Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open 2017; 2(1): e000151 doi: 10.1136/esmoopen-2016-000151
|
| 32 |
Se Jun Park, Hyunho Kim, Kabsoo Shin, Myung Ah Lee, Tae Ho Hong. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World Journal of Gastrointestinal Oncology 2019; 11(11): 1021-1030 doi: 10.4251/wjgo.v11.i11.1021
|
| 33 |
Hidenori Ando, Kiyoshi Eshima, Tatsuhiro Ishida. Neutralization of Acidic Tumor Microenvironment (TME) with Daily Oral Dosing of Sodium Potassium Citrate (K/Na Citrate) Increases Therapeutic Effect of Anti-cancer Agent in Pancreatic Cancer Xenograft Mice Model. Biological and Pharmaceutical Bulletin 2021; 44(2): 266 doi: 10.1248/bpb.b20-00825
|
| 34 |
Kiyotsugu Iede, Terumasa Yamada, Ryo Kato, Masami Ueda, Yujiro Tsuda, Shinsuke Nakashima, Katsuya Ohta, Jin Matsuyama, Masakazu Ikenaga, Shusei Tominaga. Efficacy of S‐1 in second‐line chemotherapy after nab‐paclitaxel plus gemcitabine for patients with advanced pancreatic cancer. Cancer Reports 2020; 3(2) doi: 10.1002/cnr2.1215
|
| 35 |
Si Sun, Hui Yu, Huijie Wang, Hai Zhang, Xianghua Wu, Jialei Wang, Jianhua Chang. Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma. Oncology Research and Treatment 2019; 42(3): 115 doi: 10.1159/000495700
|